vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research note issued to investors on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on vTv Therapeutics in a report on Monday, December 9th. They issued a “buy” rating and a $35.00 price target on the stock.

vTv Therapeutics Stock Up 1.2 %

Shares of vTv Therapeutics stock opened at $17.35 on Thursday. The business has a fifty day simple moving average of $17.32 and a 200-day simple moving average of $15.52. The firm has a market cap of $55.35 million, a price-to-earnings ratio of -3.83 and a beta of 1.07. vTv Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $29.19.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.32. The business had revenue of $0.02 million for the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in VTVT. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,327 shares during the period. JPMorgan Chase & Co. acquired a new stake in vTv Therapeutics during the 4th quarter valued at $25,000. Finally, FMR LLC purchased a new stake in shares of vTv Therapeutics in the third quarter valued at $2,402,000. 17.51% of the stock is owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.